Resumo

GIRALDO FORERO, Julio César et al. [T1 ENG]Pneumocystis jirovecii and SARS-CoV-2; COVID-19. Nova [online]. 2020, vol.18, n.spe35, pp.81-86.  Epub 16-Jan-2021. ISSN 1794-2470.

Pneumocystis jirovecii, is an opportunistic fungal agent that causes pneumonia (pneumocistosis) that can be fatal in people with immunocomprome status, including HIV patients with CD4+ T lymphocyte count < 200 cels/mm3 and in patients immunocompromised by other aetiologies such as solid organ transplants and cancer, among others. Many people may be healthy carriers of this etiological agent and act as a reservoir and source of infection. Articles related to co-infection between SARS-CoV-2 and opportunistic articles such as P. jirovecii and Aspergillus fumigatus begin publication, where it is argued that this viral infection has a high risk of co-infection, expressing the importance of not excluding respiratory pathogens, such as P. jirovecii, among others. Co-infection with P. jirovecii, may not be detected in patients with severe SARS-CoV-2 infection as they may share common clinical characteristics such as bilateral multifocal infiltrates and deep hypoxemia among others. Therefore, additional diagnostic tests for P. jirovecii, are necessary in patients with SARS-CoV-2 infection, especially when other clinical characteristics that may support co-infection are present such as cystic findings in thoracic CT and elevated blood levels of 1.3-D-glucan, including in the absence of classic risk factors for P. jirovecii, for the diagnosis of Pneumocystis pneumonia in patients with suspected SARS-CoV-2 infection.

Palavras-chave : Pneumocystis jirovecii; SARS-CoV-2; COVID-19. pneumonia; immunocompromised host.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )